Please select the option that best describes you:
Topics:
Radiation Oncology • Thoracic Malignancies
Given the secondary analysis of RTOG 0617, should IMRT be considered standard of care in locally advanced non-small cell lung cancer?
Answer from: Radiation Oncologist at Academic Institution
The secondary analysis of RTOG 0617 (Chun et al. JCO.2016) supports the notion that IMRT should be the standard of care for the treatment of locally advanced non-small cell lung cancer (NSCLC). This study (0617) compared chemotherapy +either 60 Gy or 74 Gy of conventionally fractionated RT. The seco...
Sign in or Register to read more
Answer from: Radiation Oncologist at Community Practice
I think some caution is warranted here. The secondary analysis from 0617 does bring up very interesting findings regarding lower V20 and a NS 2yr survival increase with IMRT versus 3D.
The most significant point though is that the trial wasn't designed to compare 3D to IMRT. Results from seco...
Answer from: Radiation Oncologist at Community Practice
The 0617 trial has delivered more puzzles than credible, reliable answers. A second secondary analysis has just appeared in JCO suggesting heart dose may also be associated. In addition to the design of high vs. low dose TRT, there was also +/- cetuximab step, and a s...